Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 10/20 | 0.63 |
| ▸ | SRC | P12931 | 8/20 | 0.63 |
| ▸ | LCK | P06239 | 5/20 | 0.63 |
| ▸ | ADK | P55263 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | ABL2 | P42684 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23471090 | 0.79 | RET (0.60) | RETSRCLCKADK | |
| SCHEMBL19732650 | 0.78 | RET (1.00) | RETSRCLCK | |
| SCHEMBL19732787 | 0.78 | EGFR (0.60) | RETSRCLCKABL1EGFR | |
| SCHEMBL5122419 | 0.78 | RET (0.61) | RETSRCLCKMTORRAB9A | |
| SCHEMBL19763856 | 0.77 | RET (1.00) | RETSRCLCK | |
| SCHEMBL6062721 | 0.69 | ADK (0.52) | ADKRAB9A | |
| SCHEMBL6062725 | 0.69 | ADK (0.52) | ADKRAB9A | |
| SCHEMBL22374279 | 0.69 | RET (0.69) | RETSRCLCK | |
| SCHEMBL30372951 | 0.68 | ADK (0.46) | RETSRCLCKADKMTOR | |
| SCHEMBL14544497 | 0.68 | ADK (0.53) | SRCADKRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-02-01 | — | — | US | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| EP-3260454-B1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10981920-B2 | — | — | 2021-04-20 | — | — | US | disclosed |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-28 | — | — | US | disclosed |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-10179788-B2 | — | — | 2019-01-15 | — | — | US | disclosed |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-18 | — | — | US | disclosed |
| EP-3269370-A1 | NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3260454-A1 | CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2017-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | RET 1/4885SRC 456/4885LCK 464/4885 |
| US-11236096-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885SRC 153/4885LCK 580/4885 |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | RET 1/4885SRC 456/4885LCK 464/4885 |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | RET 1/4885SRC 259/4885LCK 280/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885SRC 235/4885LCK 511/4885 |
| US-10179788-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885SRC 146/4885LCK 879/4885 |
| US-10233189-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885SRC 153/4885LCK 580/4885 |
| US-10787457-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885SRC 153/4885LCK 580/4885 |
| US-20180009817-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885SRC 153/4885LCK 580/4885 |
| US-11014930-B2 | Fused pyrimidine compound or salt thereof | RET, RB1, MECP2 | RET 1/4885SRC 153/4885LCK 580/4885 |
| US-20200270260-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885SRC 153/4885LCK 580/4885 |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | RET 1/4885SRC 259/4885LCK 280/4885 |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | RET 1/4885SRC 259/4885LCK 280/4885 |
| US-10981920-B2 | — | RET, GFRA1, GFRA2 | RET 1/4885SRC 146/4885LCK 879/4885 |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | RET 1/4885SRC 456/4885LCK 464/4885 |
| US-20190092776-A1 | FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, RB1, MECP2 | RET 1/4885SRC 153/4885LCK 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.